{"totalCount":4,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06985147","orgStudyIdInfo":{"id":"DISC-3405-201"},"organization":{"fullName":"Disc Medicine, Inc","class":"INDUSTRY"},"briefTitle":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","officialTitle":"A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-08-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2029-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-05-07","studyFirstSubmitQcDate":"2025-05-14","studyFirstPostDateStruct":{"date":"2025-05-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-04","lastUpdatePostDateStruct":{"date":"2026-02-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Disc Medicine, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV)."},"conditionsModule":{"conditions":["Polycythemia Vera (PV)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SEQUENTIAL","interventionModelDescription":"Up to 3 cohorts of participants are planned:\n\n* Cohort A will include 20 participants. The first 4 participants enrolled will be administered a starting dose level of Dose A DISC-3405 subcutaneous which will be followed by within-participant dose escalation. Following Safety Review Committee review of the data, an additional 16 participants will be enrolled and administered a starting dose level of Dose B DISC-3405 subcutaneous.\n* Cohort B will enroll up to 20 participants administered a dose level of Dose B DISC-3405 subcutaneous once every 4 weeks.\n* Cohort C is optional and will enroll up to 20 participants administered a dose level up to that previously studied of DISC-3405 subcutaneous once every 4 weeks.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Within-participant dose escalation","type":"EXPERIMENTAL","description":"This is an open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405.","interventionNames":["Drug: DISC-3405"]}],"interventions":[{"type":"DRUG","name":"DISC-3405","description":"DISC-3405 is administered subcutaneously.","armGroupLabels":["Within-participant dose escalation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of participants with treatment-related adverse events as assessed by CTCAE","description":"Proportion of participants with treatment-emergent adverse events","timeFrame":"Up to 365 days"},{"measure":"Incidence of clinically abnormal vital signs","description":"Proportion of participants with changes in vital signs","timeFrame":"Up to 365 days"},{"measure":"Incidence of clinically abnormal physical exam","description":"Proportion of participants with changes in physical examinations","timeFrame":"Up to 365 days"},{"measure":"Incidence of clinically abnormal electrocardiograms","description":"Proportion of participants with changes in electrocardiograms (ECGs)","timeFrame":"Up to 365 days"},{"measure":"Incidence of abnormal laboratory test results","description":"Proportion of participants with changes in clinical laboratory results","timeFrame":"Up to 365 days"}],"secondaryOutcomes":[{"measure":"Proportion of participants achieving therapeutic response, defined as absence of phlebotomy eligibility, during the maintenance period","timeFrame":"Up to 365 days"},{"measure":"Number of phlebotomies during the maintenance and optimization periods","timeFrame":"Up to 365 days"},{"measure":"Proportion of participants achieving therapeutic response, defined as absence of phlebotomy eligibility, during the optimization period","timeFrame":"Up to 365 days"},{"measure":"Proportion of participants with HCT values <45% throughout the study","timeFrame":"Up to 365 days"},{"measure":"Area under the plasma concentration versus time curve (AUC) following the first dose","timeFrame":"Up to 365 days"},{"measure":"Peak plasma concentration (Cmax) following the first dose","timeFrame":"Up to 365 days"},{"measure":"Elimination half-life (t½el) following the first dose","timeFrame":"Up to 365 days"},{"measure":"Apparent clearance (CL/F) following the first dose","timeFrame":"Up to 365 days"},{"measure":"Maximum concentration at steady state (Cmax_ss) after repeating doses","timeFrame":"Up to 365 days"},{"measure":"Pre-dose trough concentration (Ctrough) after repeating doses","timeFrame":"Up to 365 days"},{"measure":"Change from baseline for HCT","timeFrame":"Up to 365 days"},{"measure":"Change from baseline for serum hepcidin-25","timeFrame":"Up to 365 days"},{"measure":"Change from baseline for serum iron","timeFrame":"Up to 365 days"},{"measure":"Apparent volume of distribution (Vd/F)","timeFrame":"Up to 365 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged 18 years or older at the time of signing the informed consent form (ICF).\n2. Meet revised 2022 World Health Organization (WHO) criteria for the diagnosis of PV.\n3. Complete blood count values at Screening of HCT \\<45% or HCT \\<48% if followed by a phlebotomy within 2 weeks, white blood cells 4000/μL to 20,000/μL (inclusive), and platelets 100,000/μL to 1,000,000/μL (inclusive).\n4. At least 3 phlebotomies in 26 weeks before Screening or at least 5 phlebotomies in 52 weeks before Screening. At least 1 phlebotomy must be within the 12 weeks prior to Screening.\n5. Participants receiving cytoreductive therapy must have been taking for at least 6 months and be on a stable PV therapy regimen for at least 2 months for hydroxyurea, interferon or ruxolitinib with no anticipated need for dose adjustments during the study, or have decreasing dose (with medical monitor approval).\n6. Participants treated with phlebotomy alone must have stopped cytoreductive therapy 6 months before Screening.\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, or with medical monitor approval, ECOG 2.\n8. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 120 days after the last study drug dose:\n\n   1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm \\[female partner\\])\n   2. Intrauterine device in place for at least 3 months (female partner)\n   3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom \\[male or female\\] or diaphragm)\n   4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom \\[male or female\\] or diaphragm)\n9. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone \\>40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy with or without hysterectomy); surgically sterile, OR agreeable to use of highly effective contraception (listed below) on Day 1 (or earlier) and for at least 120 days after the last dose of study drug:\n\n   1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom \\[male or female\\] or diaphragm)\n   2. Intrauterine device in place for at least 3 months\n   3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom \\[male or female\\] or diaphragm)\n10. Negative pregnancy test (females of childbearing potential).\n11. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n12. Able to comply with all study procedures.\n\nExclusion Criteria:\n\n1. Clinically significant laboratory abnormalities at Screening.\n2. Participants who require phlebotomy at HCT levels \\<45%.\n3. Clinically significant thrombosis (eg, deep vein thrombosis or splenic vein thrombosis) within 2 months prior to study treatment.\n4. Clinically significant active or chronic bleeding, considered meaningful in consultation with the medical monitor, within 6 months prior to study treatment.\n5. Significant renal dysfunction, evidenced by estimated glomerular filtration rate of \\<30 mL/min/1.73 m2 at the Screening visit, as assessed locally.\n6. History of invasive malignancies within the last 5 years, except localized cured prostate cancer and cervical cancer, or other malignancies deemed acceptable by the Sponsor.\n7. Participants with in situ or stage 1 squamous cell carcinoma of the skin, in situ or stage 1 basal cell carcinoma of the skin, or in situ melanoma of the skin identified during Screening unless the cancer is adequately treated before study entry.\n8. Received busulfan, pipobroman, or phosphorus-32 within 7 months prior to Screening.\n9. Major surgery within 8 weeks before Screening or incomplete recovery from any previous surgery.\n10. A history or known allergic reaction to any investigational product excipients or history of anaphylaxis to any food or drug.\n11. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.\n12. Active human immunodeficiency virus (HIV), hepatitis B or C. A positive hepatitis or HIV result should be discussed between the Investigator and Sponsor prior to enrollment.\n13. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study.\n14. Condition or concomitant medication that would confound the ability to interpret clinical data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.\n15. If female, pregnant or breastfeeding.\n16. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days (or 5 half-lives for drugs, whichever is longer) of Screening. Previous use of other hepcidin inducing agents that may impact TMPRSS6 expression are not allowed. Previous use of hepcidin mimetics may be allowed in discussion with the Sponsor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Disc Medicine Clinical Trials","role":"CONTACT","phone":"(617) 674 9274","email":"clinicaltrials@discmedicine.com"}],"overallOfficials":[{"name":"Will Savage, MD PhD","affiliation":"Disc Medicine","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Mayo Clinic in Arizona","status":"RECRUITING","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","contacts":[{"name":"Eden Knight","role":"CONTACT","phone":"480-342-2000","email":"knight.eden@mayo.edu"},{"name":"Jeanne Palmer, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"UCLA Health","status":"RECRUITING","city":"Los Angeles","state":"California","zip":"90095","country":"United States","contacts":[{"name":"Bruck Habtemariam","role":"CONTACT","phone":"310-825-5513","email":"bhabtemariam@mednet.ucla.edu"},{"name":"Carla Petro","role":"CONTACT","phone":"310-825-5513","email":"cPetro@mednet.ucla.edu"},{"name":"Gary Schiller, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Mayo Clinic in Florida","status":"RECRUITING","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","contacts":[{"name":"Jordan Oberhaus","role":"CONTACT","phone":"904-953-6523","email":"oberhaus.jordan@mayo.edu"},{"name":"Candido Rivera, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Mayo Clinic in Minnesota","status":"RECRUITING","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","contacts":[{"name":"Chandra Hutchens","role":"CONTACT","phone":"507-266-4994","email":"hutchens.chandra@mayo.edu"},{"name":"Naseema Gangat, M.B.B.S.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Siteman Cancer Center - Washington University St. Louis","status":"RECRUITING","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","contacts":[{"name":"Nicole Gaudin","role":"CONTACT","phone":"314-362-8814","email":"nrgaudin@wustl.edu"},{"name":"Stephen Oh","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Atrium Health - Levine Cancer Center","status":"RECRUITING","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","contacts":[{"name":"Ashley Franklin","role":"CONTACT","phone":"980-442-4363","email":"Ashley.Franklin@advocatehealth.org"},{"name":"Anne Wofford","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Michael Grunwald","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Duke University","status":"RECRUITING","city":"Durham","state":"North Carolina","zip":"27705","country":"United States","contacts":[{"name":"Erin Murphy","role":"CONTACT","phone":"919-684-8964","email":"erin.murphy@duke.edu"},{"name":"Caitlyn Campbell","role":"CONTACT","phone":"919-684-8964","email":"caitlyn.campbell@duke.edu"},{"name":"Lindsay Rein, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Atrium Health Wake Forest Baptist Medical Center","status":"RECRUITING","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","contacts":[{"name":"Chelsea Torbush","role":"CONTACT","phone":"336-716-3684","email":"Chelsea.Torbush@Advocatehealth.org"},{"name":"Anne Wofford","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Ohio State University","status":"RECRUITING","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","contacts":[{"name":"Kristen Browning","role":"CONTACT","phone":"540-588-3327","email":"Kristen.Browning@osumc.edu"},{"name":"Jennifer E Vaughn, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"MD Anderson Cancer Center","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Nichole Ard","role":"CONTACT","phone":"713-792-4956","email":"NArd@mdanderson.org"},{"name":"Rhona Pinsoy","role":"CONTACT","phone":"713-792-4956","email":"mbpinsoy@mdanderson.org"},{"name":"Naveen Pemmaraju, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Washington - Fred Hutchinson Cancer Research Center","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98109","country":"United States","contacts":[{"name":"Cassidy McCarthy","role":"CONTACT","phone":"206-606-6854","email":"cmcca140@fredhutch.org"},{"name":"Anna Halpern","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.60621,"lon":-122.33207}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D011087","term":"Polycythemia Vera"}],"ancestors":[{"id":"D019046","term":"Bone Marrow Neoplasms"},{"id":"D019337","term":"Hematologic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001855","term":"Bone Marrow Diseases"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D009196","term":"Myeloproliferative Disorders"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05320198","orgStudyIdInfo":{"id":"DISC-0974-102"},"organization":{"fullName":"Disc Medicine, Inc","class":"INDUSTRY"},"briefTitle":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","officialTitle":"RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-06-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-03-15","studyFirstSubmitQcDate":"2022-04-01","studyFirstPostDateStruct":{"date":"2022-04-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-22","lastUpdatePostDateStruct":{"date":"2026-01-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Disc Medicine, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia."},"conditionsModule":{"conditions":["Myelofibrosis; Anemia","Anemia","Myelofibrosis","Myelofibrosis Due to and Following Polycythemia Vera","Primary Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Myelodysplastic Syndromes"],"keywords":["Myeloproliferative Neoplasm","Myeloproliferative Disorders"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Phase 1b: Dose Escalation","type":"EXPERIMENTAL","description":"In the Phase 1b (dose-escalation) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.","interventionNames":["Drug: DISC-0974"]},{"label":"Phase 2: Expansion","type":"EXPERIMENTAL","description":"In the Phase 2 (expansion) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.","interventionNames":["Drug: DISC-0974"]}],"interventions":[{"type":"DRUG","name":"DISC-0974","description":"DISC-0974 is administered subcutaneously.","armGroupLabels":["Phase 1b: Dose Escalation","Phase 2: Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of treatment-emergent adverse events (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Incidence of clinically abnormal vital signs (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Incidence of clinically abnormal physical exam (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Incidence of clinically abnormal electrocardiograms (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Incidence of abnormal laboratory test results (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Transfusion-dependent (TD) high cohort: transfusion independence, defined as the absence of packed red blood cell (PRBC) transfusions over any rolling 12-week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"TD low cohort: transfusion independence, defined as the absence of PRBC transfusions over any rolling 16 week interval during the treatment period with a minimum Hgb of 7 g/dL (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"Non-transfusion-dependent (nTD) cohort: anemia response, defined as the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 2 only)","timeFrame":"up to 225 days"}],"secondaryOutcomes":[{"measure":"Anemia response defined per IWG-MRT criteria (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"TD high and TD low participants will be evaluated for absence of PRBC transfusions for a consecutive, \"rolling\" 12 week interval during the treatment period (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"TD high participants will be evaluated for absence of PRBC transfusions with minimum Hgb of 7 g/dL during a terminal 12 week interval during the treatment period (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"TD low participants will be evaluated for absence of PRBC transfusions with minimum Hgb of 7 g/dL during any rolling 16-week interval during the treatment period (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"nTD participants will be evaluated for ≥1.5 g/dL increase from baseline Hgb levels during the treatment period (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"nTD participants will be evaluated for the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Safety, tolerability, PK, and PD of DISC-0974 following repeated SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts (collectively referred to as MDS) and anemia (Phase 1b only)","timeFrame":"up to 225 days"},{"measure":"Proportion of participants achieving a mean Hgb increase ≥1 g/dL or ≥2 g/dL from baseline over any rolling 12-week period in absence of RBC transfusions in each cohort (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Change from baseline in concentration of iron laboratory parameters (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Change from baseline in concentration of hematologic laboratory parameters (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Rate and units of RBC transfusion per participant month during the treatment period for each cohort (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Transfusion-dependent cohorts will be evaluated for proportion of participants who reduce their transfusion requirement by 50%, compared to baseline, over any rolling 12-week period during treatment (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"nTD participants will be evaluated for longest duration of mean Hgb increase of ≥1.5 g/dL from baseline during the treatment period (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Mean change in Hgb over 12-week treatment periods will be evaluated for all cohorts (nTD, TD low, TD high) (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Maximum duration of RBC-transfusion-independent response for TD participants (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Proportion of participants that require dose escalation in each cohort (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Proportion of participants that improve Functional Assessment of Cancer Therapy-Anemia (FACT-An) subscale by at least 3 points in each cohort during the treatment period (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Mean hemoglobin increase of ≥1.5 g/dL over a rolling 12-week interval and an increase in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue of 3 points by the end of study (EOS) for nTD participants (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"TD high cohort will be evaluated for absence of packed red blood cell (PRBC) transfusions a terminal 12 week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"TD low cohort: will be evaluated for the absence of PRBC transfusions a terminal 16 week interval during the treatment period with a minimum Hgb of 7 g/dL (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Non-transfusion-dependent (nTD) cohort: anemia response, defined as the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Incidence of treatment-emergent adverse events (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"Incidence of clinically abnormal vital signs (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"Incidence of clinically abnormal physical exam (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"Incidence of clinically abnormal electrocardiogram (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"Incidence of abnormal laboratory test results (Phase 2 only)","timeFrame":"up to 225 days"},{"measure":"Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy as assessed by TEAEs, vital signs, physical examinations, ECGs, and blood and urine testing (Phase 2 only)","timeFrame":"225 days"},{"measure":"Cmax-Maximum drug concentration measured in plasma (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Tmax-Time of maximum drug concentration (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"AUC-Area under the drug concentration time curve (Phase 1b and 2)","timeFrame":"up to 225 days"},{"measure":"Additional PK analysis using a population PK analysis approach may be considered. (Phase 1b and 2)","timeFrame":"up to 225 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for Participants with MF and Anemia\n\nParticipants are eligible for the study if all of the following criteria apply:\n\n1. Age 18 years or older at the time of signing the informed consent form (ICF).\n2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.55\n\n   For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.\n3. Washout of at least 28 days prior to Screening of the following treatments:\n\n   1. Androgens\n   2. EPO\n   3. Cladribine\n   4. Immunomodulators (lenalidomide, thalidomide)\n   5. Luspatercept/sotatercept\n   6. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.\n\n   Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.\n4. Anemia:\n\n   For Phase 1b: Hgb \\<10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb \\<10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.\n\n   For Phase 2:\n\n   TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening nTD cohort: Non-transfusion dependence, baseline Hgb \\<10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion\n5. Stable dosing of MF-directed therapy:\n\n   1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.\n   2. Interferon alpha stable dosing for at least 12 weeks prior to Screening.\n   3. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD high, TD low, and nTD cohorts, JAK inhibitors allowed include momelotinib, pacritinib, fedratinib, and ruxolitinib.\n   4. If the participant discontinues JAK inhibitor (including momelotinib/pacritinib/ruxolitinib/fedratinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.\n6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.\n7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.\n8. TSAT \\<75% (local lab acceptable).\n9. Liver iron concentration by MRI \\<7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.\n10. Serum ferritin ≥50 µg/L at Screening.\n11. Platelet count ≥25,000/µL and \\<1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count \\<50,000/µL at Screening.\n12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.\n13. Aspartate aminotransferase (AST) and ALT \\<3x upper limit of normal (ULN) at Screening.\n14. Direct bilirubin \\<2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.\n15. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    1. Stable hormonal contraceptive (≥3 months; female partner)\n    2. Intrauterine device in place for at least 3 months (female partner)\n    3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)\n    4. Confirmed successful vasectomy\n16. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \\>40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:\n\n    1. Stable hormonal contraceptive (≥3 months)\n    2. Intrauterine device in place for at least 3 months\n    3. Tubal ligation or single male partner with vasectomy\n17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).\n18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n19. Able to comply with all study procedures.\n\nInclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia\n\nParticipants are eligible for the MDS exploratory cohort if all of the following criteria apply:\n\n1. Age 18 years or older at the time of signing the ICF.\n2. Molecular International Prognostic Scoring System (IPSS-M) classification of very low, low, or intermediate (ie, lower risk) MDS-ringed sideroblasts (RS) negative, MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), or Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN-U) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.\n3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:\n\n   1. Androgens\n   2. EPO-stimulating agents\n   3. Luspatercept\n   4. Sotatercept (ACE-011)\n   5. Imetelstat\n   6. Granulocyte colony-stimulating factor (G-CSF) OR granulocyte-macrophage CSF (GM-CSF)\n   7. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.\n4. Anemia:\n\n   1. Baseline Hgb of \\<10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb \\<10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening\n   2. Medical history of ≤24 units of PRBC for MDS and anemia\n5. ECOG performance score ≤2\n6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening\n7. TSAT \\<75% (local lab acceptable)\n8. Liver iron concentration by MRI \\<7 mg/g dry weight within 3 months of eligibility confirmation by central review\n9. Serum ferritin ≥50 μg/L at Screening\n10. Platelet count ≥25,000/μL and \\<1,000,000/μL, and total WBC count \\<50,000/μL at Screening or otherwise approved by Sponsor\n11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula\n12. AST and ALT \\<3x ULN at Screening\n13. Direct bilirubin \\<2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.\n14. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    1. Stable hormonal contraceptive (≥3 months; female partner)\n    2. Intrauterine device in place for at least 3 months (female partner)\n    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)\n    4. Confirmed successful vasectomy\n15. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum FSH levels \\>40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:\n\n    1. Stable hormonal contraceptive (≥3 months)\n    2. Intrauterine device in place for at least 3 months\n    3. Tubal ligation or single male partner with vasectomy\n16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).\n17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n18. Able to comply with all study procedures.\n\nExclusion Criteria Exclusion Criteria for Participants with MF and Anemia\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical History, Participants with MF and Anemia\n\n1. Hereditary hemochromatosis\n2. Hemoglobinopathy or intrinsic RBC defect associated with anemia\n3. Total splenectomy\n4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression\n5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding\n6. Active immune-mediated hemolytic anemia\n7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening\n8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery\n9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:\n\n   1. basal or squamous cell carcinoma\n   2. carcinoma in situ of the cervix or the breast\n   3. histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \\[TNM\\] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement\n10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening\n11. Known allergic reaction to any study drug excipient\n12. A history of anti-drug antibody formation\n13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction \\<35%\n14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load\n15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)\n\n    Treatment History, Medical History, Participants with MF and Anemia\n16. Iron chelation therapy in the 28 days prior to Screening\n17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening\n\n    Laboratory Exclusions, Medical History, Participants with MF and Anemia\n18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening\n19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening\n\n    Miscellaneous, Medical History, Participants with MF and Anemia\n20. Pregnant or lactating\n21. Condition or concomitant medication that would confound the ability to interpret study data\n22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study\n23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening\n\nExclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia\n\nParticipants are excluded from the MDS exploratory cohort if any of the following criteria apply:\n\nMedical History, Participants with MDS and Anemia\n\n1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases\n2. Peripheral blasts ≥5%\n3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy\n4. Prior treatment with \\>3 anemia-directed therapies (unless otherwise approved by Sponsor) including:\n\n   1. Luspatercept\n   2. Sotatercept (ACE-011)\n   3. EPO-stimulating agent\n   4. Imetelstat\n5. Hereditary hemochromatosis\n6. Hemoglobinopathy or intrinsic RBC defect associated with anemia\n7. Total splenectomy\n8. Hematopoietic cell transplant within the past 10 years\n9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding\n10. Active immune-mediated hemolytic anemia\n11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening\n12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery\n13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:\n\n    1. basal or squamous cell carcinoma\n    2. carcinoma in situ of the cervix or the breast\n    3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement\n14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening\n15. Known allergic reaction to any study drug excipient\n16. A history of antidrug antibody formation\n17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction \\<35%\n18. Active hepatitis B or C, or HIV with detectable viral load\n19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)\n\n    Treatment History, Participants with MDS and Anemia\n20. Iron chelation therapy in the 28 days prior to Screening\n21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening\n\n    Laboratory Exclusions, Participants with MDS and Anemia\n22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening\n\n    Miscellaneous, Participants with MDS and Anemia\n23. Pregnant or lactating\n24. Condition or concomitant medication that would confound the ability to interpret study data\n25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study\n26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Disc Medicine Clinical Trials","role":"CONTACT","phone":"(617) 674 9274","email":"clinicaltrials@discmedicine.com"}],"overallOfficials":[{"name":"Will Savage, MD PhD","affiliation":"Disc Medicine","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"City of Hope - Duarte","status":"RECRUITING","city":"Duarte","state":"California","zip":"91010","country":"United States","contacts":[{"name":"Samantha Humpal","role":"CONTACT","email":"shumpal@coh.org"},{"name":"Shama Hussain","role":"CONTACT","email":"shhussain@coh.org"},{"name":"Idoroenyi Amanam, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"City of Hope - Lennar","status":"RECRUITING","city":"Irvine","state":"California","zip":"92618","country":"United States","contacts":[{"name":"Grace Bae","role":"CONTACT","email":"gbae@coh.org"},{"name":"Dina Hassan","role":"CONTACT","email":"dhassan@coh.org"},{"name":"Idoroenyi Amanam, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"Mayo Clinic Jacksonville","status":"RECRUITING","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","contacts":[{"name":"Latesha Jones","role":"CONTACT","phone":"904 953 4564","email":"jones.latesha@mayo.edu"},{"name":"James Foran, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Sylvester Cancer Center - U Miami","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33136","country":"United States","contacts":[{"name":"Israel Zagales","role":"CONTACT","email":"israelz@med.miami.edu"},{"name":"Jennifer Posada","role":"CONTACT","email":"jxp2320@med.miami.edu"},{"name":"Sangeetha Venugopal, MD, MS","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Moffitt Cancer Center","status":"RECRUITING","city":"Tampa","state":"Florida","zip":"33612","country":"United States","contacts":[{"name":"Paul Ciero","role":"CONTACT","email":"paul.ciero@moffitt.org"},{"name":"Andrew Kuykendall, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Emory Winship Cancer Institute","status":"RECRUITING","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","contacts":[{"name":"Karin Chappelle","role":"CONTACT","email":"karin.chappelle@emory.edu"},{"name":"Danielle Oliver","role":"CONTACT","email":"danielle.oliver@emory.edu"},{"name":"Anthony Hunter, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"University of Michigan","status":"RECRUITING","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","contacts":[{"name":"Linda Kemp","role":"CONTACT","phone":"734-232-4312","email":"lfarhat@med.umich.edu"},{"name":"Moshe Talpaz, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Mayo Clinic Rochester","status":"RECRUITING","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","contacts":[{"name":"Chandra Hutchens","role":"CONTACT","email":"hutchens.chandra@mayo.edu"},{"name":"Naseema Gangat, MBBS","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Washington University St.Louis","status":"RECRUITING","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","contacts":[{"name":"Nicole Gaudin","role":"CONTACT","email":"nrgaudin@wustl.edu"},{"name":"Amy Zhou, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Memorial Sloan Kettering Cancer Center","status":"RECRUITING","city":"New York","state":"New York","zip":"10021","country":"United States","contacts":[{"name":"Samantha Mcfadden","role":"CONTACT","phone":"612-360-1081","email":"macfads@mskcc.org"},{"name":"Naa-Akomaah Yeboah","role":"CONTACT","phone":"612-360-1081","email":"yeboahn1@mskcc.org"},{"name":"Prioty Islam, MD, MSc","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Icahn School of Medicine at Mount Sinai","status":"RECRUITING","city":"New York","state":"New York","zip":"10029","country":"United States","contacts":[{"name":"MPD Research Team at Mount Sinai","role":"CONTACT","phone":"212-241-3417","email":"ResearchMPD@mssm.edu"},{"name":"Gabriela Bello","role":"CONTACT","email":"gabriela.bello@mssm.edu"},{"name":"John Mascarenhas, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Atrium Health Wake Forest Baptist","status":"RECRUITING","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","contacts":[{"name":"Libyadda Mosley","role":"CONTACT","email":"limosley@wakehealth.edu"},{"name":"Anne Wofford, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Gabrail Cancer Center Research","status":"TERMINATED","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Cleveland Clinic","status":"RECRUITING","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","contacts":[{"name":"Sharon Sanders","role":"CONTACT","phone":"216 448-4478","email":"sanders2@ccf.org"},{"name":"Sunny Dickerson","role":"CONTACT","email":"dickers3@ccf.org"},{"name":"Aaron Gerds, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Oregon Health and Science University","status":"RECRUITING","city":"Portland","state":"Oregon","zip":"97239","country":"United States","contacts":[{"name":"Keshara Bandara","role":"CONTACT","email":"bandara@ohsu.edu"},{"name":"Ronan Swords, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Sargon Research - Pennsylvania Cancer Specialists and Research Center","status":"WITHDRAWN","city":"Gettysburg","state":"Pennsylvania","zip":"17325","country":"United States","geoPoint":{"lat":39.83093,"lon":-77.2311}},{"facility":"University of Pennsylvania","status":"RECRUITING","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","contacts":[{"name":"Thomas Greenwood","role":"CONTACT","phone":"267-854-6712","email":"thomas.greenwood@pennmedicine.upenn.edu"},{"name":"Elizabeth Hexner, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"MD Anderson","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Kurt Schreoder","role":"CONTACT","phone":"346 725 5139","email":"kdschroe@mdanderson.org"},{"name":"Prithviraj Bose, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Washington","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98109","country":"United States","contacts":[{"name":"Cassidy McCarthy","role":"CONTACT","phone":"206 602 1172","email":"cmcca140@fredhutch.org"},{"name":"Anna Halpern, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Medical College of Wisconsin","status":"RECRUITING","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","contacts":[{"name":"Kristin Komnick","role":"CONTACT","phone":"414-805-5276","email":"kkomnick@mcw.edu"},{"name":"Laura Michaelis, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":43.0389,"lon":-87.90647}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D055728","term":"Primary Myelofibrosis"},{"id":"D000740","term":"Anemia"},{"id":"D009190","term":"Myelodysplastic Syndromes"},{"id":"D009196","term":"Myeloproliferative Disorders"}],"ancestors":[{"id":"D001855","term":"Bone Marrow Diseases"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07368972","orgStudyIdInfo":{"id":"DISC-0974-201"},"organization":{"fullName":"Disc Medicine, Inc","class":"INDUSTRY"},"briefTitle":"Study of DISC-0974-201 in Participants With IBD and Anemia","officialTitle":"RALLY-IBD: A Phase 2 Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of DISC-0974 in Participants With Inflammatory Bowel Disease and Anemia of Inflammation"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2026-02-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2026-01-22","studyFirstSubmitQcDate":"2026-01-23","studyFirstPostDateStruct":{"date":"2026-01-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-24","lastUpdatePostDateStruct":{"date":"2026-02-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Disc Medicine, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation."},"conditionsModule":{"conditions":["Inflammatory Bowel Disease (IBD)","Anemia","Inflammatory Bowel Disease (IBD); Anemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":21,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Active","type":"EXPERIMENTAL","description":"DISC-0974 60 mg (n = 14) administered subcutaneously (SC) every 28 days for 3 doses","interventionNames":["Drug: DISC-0974"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo (n = 7) administered SC every 28 days for 3 doses","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"DISC-0974","description":"DISC-0974 is administered subcutaneously.","armGroupLabels":["Active"]},{"type":"DRUG","name":"Placebo","description":"Placebo is administered subcutaneously","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Maximal change from baseline in Hgb through Day 85","timeFrame":"up to 85 days"}],"secondaryOutcomes":[{"measure":"Incidence of treatment-emergent adverse events","timeFrame":"Up to 85 days"},{"measure":"Incidence of clinically abnormal vital signs","timeFrame":"Up to 85 days"},{"measure":"Incidence of clinically abnormal physical exam","timeFrame":"Up to 85 days"},{"measure":"Incidence of clinically abnormal electrocardiograms","timeFrame":"Up to 85 days"},{"measure":"Incidence of abnormal laboratory test results","timeFrame":"Up to 85 days"},{"measure":"Change from baseline in concentration of iron laboratory parameters","timeFrame":"Up to 85 days"},{"measure":"Change from baseline of reticulocyte count","timeFrame":"Up to 85 days"},{"measure":"Change from baseline of reticulocyte hemoglobin content (CHr)","timeFrame":"Up to 85 days"},{"measure":"Change from baseline of red blood cell (RBC) count","timeFrame":"Up to 85 days"},{"measure":"Mean change in Hgb from baseline through Day 85","description":"Proportion of participants that achieve Hgb increase ≥1 g/dL and ≥ 2 g/dL through Day 85. Proportion of participants that hit dose holding criteria (Hgb increase of ≥2 g/dL from baseline or absolute Hgb of ≥15 g/dL)","timeFrame":"Up to 85 days"},{"measure":"Cmax-Maximum drug concentration measured in plasma","timeFrame":"Up to 85 days"},{"measure":"Tmax-Time of maximum drug concentration","timeFrame":"Up to 85 days"},{"measure":"AUC-Area under the drug concentration time curve","timeFrame":"Up to 85 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nParticipants must meet all the following criteria at screening (unless otherwise specified) to be eligible for enrollment in the study:\n\n1. Aged ≥18 years at the time of signing informed consent.\n2. Established diagnosis of IBD (CD, UC, or IBD-unclassified) based on documented findings on both endoscopy and histopathology.\n3. Baseline endoscopy at screening with modified Mayo Score for UC and CDAI for Crohn's Disease to include mild disease as defined below:\n\n   a. CDAI of \\<220 and SES-CD of 0 to 6 (CD/IBD-unclassified) modified Mayo Score of \\<5 points and Mayo endoscopic subscore of 0 to 1 (UC/IBD-unclassified).\n4. Are symptomatic from anemia as assessed by the Investigator despite optimized, stable conventional IBD-directed therapy for 3 months.\n5. Hgb ≥7 AND \\<12 g/dL for females and ≥7 AND \\<13 g/dL for males (local lab) at screening.\n6. Have symptomatic anemia defined as:\n\n   1. Hgb ≤10 g/dL and symptomatic as assessed by Investigator (fatigue, shortness of breath at rest or on minimal exertion, palpitations, tachycardia, orthostatic hypotension or dizziness), or\n   2. Hgb \\>10 g/dL and a minimum score of 4 on the Numeric Rating Scale for Fatigue.\n7. Serum ferritin ≥75 μg/L at screening (local lab).\n8. AST and ALT \\<2× upper limit of normal (ULN) at screening.\n9. Total and direct bilirubin \\<ULN at screening.\n10. Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.\n11. If female, then EITHER postmenopausal (defined as at least 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) \\>40 mIU/mL, or at least 6 weeks following surgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) during the study and for at least 8 weeks after the last dose of study drug:\n\n    * Stable hormonal contraceptive (≥3 months)\n    * Intrauterine device in place for at least 3 months\n    * Tubal ligation or single male partner with vasectomy\n12. If a male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    * Stable hormonal contraceptive (≥3 months; female partner)\n    * Intrauterine device in place for at least 3 months (female partner)\n    * Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)\n    * Confirmed successful vasectomy\n13. Able to understand and provide written informed consent.\n14. Able to comply with all study procedures.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria at screening are not eligible for study enrollment:\n\n1. Treatment within 2 days prior to screening with oral iron or iron-containing supplements. Participants may be considered for the study if they undergo a 2-day washout period prior to screening labs for oral iron or iron-containing supplements. Between screening and 2 days prior to Day 1 visit, participants may continue oral iron or iron-containing supplements at the discretion of the Investigator, but any study-related lab draws will require a 48-hour washout from oral iron.\n2. Treatment within 30 days prior to screening with any of the following anemia treatments: blood transfusion, EPO-stimulating agent (ESA), or IV iron. Participants may be considered for the study if they undergo a 30-day washout period for ESAs or IV iron prior to screening labs.\n3. Planned change in IBD directed therapy within 3 months of screening.\n4. Moderate or severe IBD assessed during screening period. Defined as:\n\n   1. CD/IBD-unclassified: participants with a CDAI score ≥220 or SES-CD ≥7\n   2. UC/IBD-unclassified: modified Mayo Score of ≥6 or endoscopic subscore of 3\n   3. Fever, tachycardia, or anticipated need for surgery in the next 3 months\n5. Hospitalization within 30 days prior to screening.\n6. Positive direct antiglobulin test with reactive eluate at screening or medical history at screening of active hemolytic anemia.\n7. Gross gastrointestinal blood loss (eg, visible rectal bleeding, hematochezia, melena) within 4 weeks prior to screening.\n8. Active gastrointestinal bleeding requiring hospitalization, blood transfusion, or endoscopy hemostasis within 8 weeks prior to screening.\n9. Current use of Janus kinase (JAK) inhibitor.\n10. History of hereditary hemochromatosis.\n11. History of Primary Sclerosis Cholangitis.\n12. History of hemoglobinopathy or intrinsic RBC defect associated with anemia.\n13. History of total splenectomy.\n14. Hematopoietic stem cell or solid organ transplant within the past 10 years.\n15. Medical history of anemia from Vitamin B12 or folate deficiency or infection in the 3 months prior to screening.\n16. Stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months prior to screening.\n17. Medical history of clinically significant thrombotic disorder.\n18. If female, pregnant or breastfeeding.\n19. Any major surgery within 8 weeks before screening or incomplete recovery from any previous surgery.\n20. Current or recent systemic corticosteroid use (within 3 months of screening).\n21. Endoscopic abnormalities concerning for colon cancer on baseline endoscopy.\n22. History of malignancy within the last 3 years. The following history/concurrent conditions are allowed: basal or squamous cell carcinoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis clinical staging system). A history of completed treatment (medical or surgical) of Stage 1-2 cancers may be permitted with prior Sponsor agreement.\n23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days of screening.\n24. A history or known allergic reaction to any investigational product excipients.\n25. History of ADA formation with anaphylaxis.\n26. History of inadequately controlled heart failure (New York Heart Association Classification 3 or 4) and/or have a history of left ventricular ejection fraction \\<35%.\n27. Uncontrolled fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement, despite appropriate treatment).\n28. Active infectious gastroenteritis including clostridium difficile colitis or viral enteritis (eg, cytomegalovirus).\n29. HIV positive, active hepatitis B virus surface antigen (HBV), or active hepatitis C virus antibody (HCV).\n30. Significant medical condition, laboratory abnormality, or psychiatric condition that would prevent the patient from participating in the study.\n31. Any condition or concomitant medication that would confound the ability to interpret data from the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Disc Medicine Clinical Trials","role":"CONTACT","phone":"(617) 674 9274","email":"clinicaltrials@discmedicine.com"}],"overallOfficials":[{"name":"Will Savage, MD, PhD","affiliation":"Disc Medicine","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clinical Research of Osceola, LLC","status":"RECRUITING","city":"Kissimmee","state":"Florida","zip":"34741","country":"United States","contacts":[{"name":"Victor Sanchez","role":"CONTACT","phone":"407-954-4016","email":"vsanchez@crosceola.com"},{"name":"Basher Atiquzzaman","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":28.30468,"lon":-81.41667}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D015212","term":"Inflammatory Bowel Diseases"},{"id":"D000740","term":"Anemia"}],"ancestors":[{"id":"D005759","term":"Gastroenteritis"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06910358","orgStudyIdInfo":{"id":"DISC-1459-301"},"secondaryIdInfos":[{"id":"2024-520407-27-00","type":"CTIS"}],"organization":{"fullName":"Disc Medicine, Inc","class":"INDUSTRY"},"briefTitle":"Study of Bitopertin in Participants With EPP or XLP (APOLLO)","officialTitle":"APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)","acronym":"APOLLO"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-04-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-03-17","studyFirstSubmitQcDate":"2025-03-27","studyFirstPostDateStruct":{"date":"2025-04-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-11","lastUpdatePostDateStruct":{"date":"2026-02-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Disc Medicine, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are:\n\n* Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP.\n* How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment.\n\nResearchers will compare bitopertin to a placebo look-alike substance that contains no drug.\n\nParticipants will complete daily questionnaires and attend study visits for assessments."},"conditionsModule":{"conditions":["Erythropoietic Protoporphyria (EPP)","X-Linked Protoporphyria (XLP)"],"keywords":["EPP","XLP","DISC-1459","RO4917838","porphyria"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"DISC-1459 oral dose","type":"EXPERIMENTAL","interventionNames":["Drug: DISC-1459"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"Oral dose, once a day for 24 weeks","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"DISC-1459","description":"Oral dose, once a day for 24 weeks","armGroupLabels":["DISC-1459 oral dose"],"otherNames":["Bitopertin","RO4917838"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment","timeFrame":"24 weeks"},{"measure":"Percent change from baseline in whole-blood metal-free PPIX levels at 6 months","timeFrame":"24 weeks"},{"measure":"Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment period","timeFrame":"24 weeks"}],"secondaryOutcomes":[{"measure":"Occurrence of phototoxic reactions over the 6-month treatment period","timeFrame":"24 weeks"},{"measure":"Cumulative total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) over the 6-month (24-week) treatment period","timeFrame":"24 weeks"},{"measure":"Change from baseline in 2-week average daily sunlight exposure time (minutes) to first prodromal symptom (eg, burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at 6 months","timeFrame":"24 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged 12 years or older at the time of study consent.\n2. Diagnosis of EPP or XLP, based on medical history by ferrochelatase (FECH) or aminolevulinic acid synthase 2 (ALAS2) genotyping or by biochemical porphyrin analysis.\n3. Minimum daily Sun Exposure Diary compliance ≥85% on Days -14 through Day -1, inclusive, during screening, and at least 1 successfully completed Sun Exposure Challenge (adults only, as this assessment is optional for adolescents) or historical recall of time to prodrome\n4. Body weight ≥32 kg (ages 12 to \\<18 years), body mass index ≥18.5 kg/m2 (ages ≥18 years) at screening.\n5. Washout of at least 2 months prior to screening of afamelanotide and dersimelagon, if applicable.\n6. Aspartate aminotransferase and alanine transaminase \\<3× upper limit of normal (ULN)and total bilirubin \\<2× ULN (unless documented Gilbert syndrome) at screening. Albumin \\>lower limit of normal (LLN).\n7. Willing to practice highly effective methods of birth control (both males who have partners of childbearing potential and females of childbearing potential during screening, while taking study drug, and for at least 30 days after the last dose of study drug).\n\nExclusion Criteria:\n\n1. Major surgery within 8 weeks before screening or incomplete recovery from any previous surgery.\n2. Other than EPP or XLP, an inherited intrinsic or extrinsic red cell disease associated with anemia.\n3. Known hypersensitivity to any component of the study drug.\n4. History of liver transplantation or anticipated need for liver transplantation.\n5. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.\n6. Active human immunodeficiency virus (HIV), active hepatitis B or C.\n7. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study.\n8. Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.\n\n   Treatment History:\n9. Prior exposure to bitopertin.\n10. Concurrent or planned treatment with afamelanotide or dersimelagon during the study period.\n11. Treatment with opioids for any period \\>7 days in the 2 months prior to screening or anticipated to require opioid use for \\>7 days at any point during the study.\n12. New treatment for anemia, including initiation of iron supplementation, within 1 month of screening.\n13. Current or planned use of any drugs or herbal remedies known to be strong or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 enzymes for 28 days prior to the first dose and throughout the study.\n14. Current or planned treatment with antipsychotic medication.\n\n    Laboratory Exclusions:\n15. Hemoglobin \\<10 g/dL at screening.\n\n    Miscellaneous:\n16. Participation in other interventional clinical studies within 30 days prior to screening.\n17. If female, pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Disc Medicine Clinical Trials","role":"CONTACT","phone":"(617) 674 9274","email":"clinicaltrials@discmedicine.com"}],"overallOfficials":[{"name":"Will Savage, MD, PhD","affiliation":"Disc Medicine","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Marvel Clinical Research","status":"RECRUITING","city":"Huntington Beach","state":"California","zip":"92647","country":"United States","contacts":[{"name":"Matthew Campos","role":"CONTACT","phone":"714-375-5970","email":"info@marvelclinical.com"},{"name":"Manuchehr Darani, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.6603,"lon":-117.99923}},{"facility":"University of California San Francisco","status":"RECRUITING","city":"San Francisco","state":"California","zip":"94143","country":"United States","contacts":[{"name":"Jackie Lam","role":"CONTACT","phone":"415-502-7750","email":"Jacqueline.lam@ucsf.edu"},{"name":"Bruce Wang, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"University of Miami Miller School of Medicine","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33146","country":"United States","contacts":[{"name":"Felisa Padilla","role":"CONTACT","phone":"305-243-7343","email":"fcp25@med.miami.edu"},{"name":"Cynthia Levy, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Massachusetts General Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","contacts":[{"name":"Narmene Bensaber","role":"CONTACT","phone":"206-681-0218","email":"nbensaber@mgh.harvard.edu"},{"name":"Amy Dickey, MD, MSC","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"MetroBoston Clinical Partners","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02135","country":"United States","contacts":[{"name":"Stella Schandorf","role":"CONTACT","phone":"781-535-1174","email":"gzhang@metrobostoncp.com"},{"name":"Mark S Amster, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Henry Ford Health System","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","contacts":[{"name":"Jennifer Creasor","role":"CONTACT","phone":"313-916-0427","email":"jcreaso2@hfhs.org"},{"name":"Tasneem Mohammad, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Mount Sinai Hospital","status":"RECRUITING","city":"New York","state":"New York","zip":"10029","country":"United States","contacts":[{"name":"Georgia MacDonald","role":"CONTACT","phone":"646-946-6923","email":"georgia.macdonald@mssm.edu"},{"name":"Manisha Balwani, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Wake Forest University","status":"RECRUITING","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","contacts":[{"name":"Dee Faust","role":"CONTACT","phone":"336-713-1442","email":"Denise.Faust@advocatehealth.org"},{"name":"Herbert Bonkovsky, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Remington-Davis Clinical Research","status":"RECRUITING","city":"Columbus","state":"Ohio","zip":"43215","country":"United States","contacts":[{"name":"Imani Ramos","role":"CONTACT","phone":"614-487-2560","email":"derm@remdavis.com"},{"role":"CONTACT","email":"iramos@remdavis.com"},{"name":"Edward M Cordasco, DO, FCCP","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"University of Texas Medical Branch","status":"RECRUITING","city":"Galveston","state":"Texas","zip":"77550","country":"United States","contacts":[{"name":"Rochelle Simmons","role":"CONTACT","phone":"409-772-9103","email":"rrsimmon@utmb.edu"},{"name":"Karl Anderson, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.30135,"lon":-94.7977}},{"facility":"University of Washington","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98195","country":"United States","contacts":[{"name":"Cassidy McCarthy","role":"CONTACT","phone":"206-606-2446","email":"cmcca140@fredhutch.org"},{"name":"Sioban Keel, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Royal Prince Alfred Hospital","status":"RECRUITING","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","contacts":[{"name":"Darcie Kavanagh","role":"CONTACT","phone":"(02) 9515 5186","email":"darcie.kavanagh@health.nsw.gov.au"},{"name":"A/Prof Peter Stewart","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"The Royal Melbourne Hospital","status":"RECRUITING","city":"Parkville","state":"Victoria","zip":"3050","country":"Australia","contacts":[{"name":"Dermatology Research","role":"CONTACT","phone":"+61393424542","email":"dermatologyresearch@mh.org.au"},{"name":"A/Prof Gayle Ross","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"University of Alberta","status":"RECRUITING","city":"Edmonton","state":"Alberta","zip":"T6G 2R3","country":"Canada","contacts":[{"name":"Principle Investigator","role":"CONTACT","phone":"780-492-3550","email":"Bruce.Ritchie@ualberta.ca"},{"name":"Bruce Ritchie","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"CHU de Nantes - Hôtel Dieu, Service de dermatologie","status":"RECRUITING","city":"Nantes","state":"France","zip":"44093","country":"France","contacts":[{"name":"Dr. Marie Le Moigne","role":"CONTACT","phone":"+33 2 44 76 83 90","email":"marie.lemoigne@chu-nantes.fr"},{"name":"Dr. Marie Le Moigne","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard","status":"RECRUITING","city":"Paris","state":"France","zip":"75018","country":"France","contacts":[{"name":"Jonathan Lehacaut","role":"CONTACT","phone":"+ 33 1 40 25 68 75","email":"jonathan.lehacaut@aphp.fr"},{"name":"Laurent Gouya","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Charité - Universitätsmedizin Berlin, Institute of Allergology","status":"RECRUITING","city":"Berlin","state":"Germany","zip":"12203","country":"Germany","contacts":[{"name":"Principle Investigator","role":"CONTACT","phone":"+49 30 450 518214","email":"manuel.pereira@charite.de"},{"name":"Manuel Pereira","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Klinikum Chemnitz gGmbH","status":"RECRUITING","city":"Chemnitz","state":"Saxony","zip":"09116","country":"Germany","contacts":[{"name":"Dr med. Ilja Kubisch","role":"CONTACT","phone":"0371 333-33236","email":"i.kubisch@skc.de"},{"name":"Dr med. Ilja Kubisch","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":50.8357,"lon":12.92922}},{"facility":"Erasmus MC","status":"RECRUITING","city":"Rotterdam","state":"The Netherlands","zip":"3015 GD","country":"Netherlands","contacts":[{"name":"Janneke Langendonk","role":"CONTACT","phone":"+31 (0)10 7040574","email":"EPP@erasmusmc.nl"},{"name":"Janneke Langendonk","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Helse Bergen","status":"RECRUITING","city":"Bergen","state":"Norway","zip":"5032","country":"Norway","contacts":[{"name":"Study Coordinator","role":"CONTACT","phone":"+47 55973170","email":"porfyri@helse-bergen.no"},{"name":"Aasne Karine Aarsand","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":60.39299,"lon":5.32415}},{"facility":"Hospital Clinic de Barcelona","status":"RECRUITING","city":"Barcelona","state":"Spain","zip":"08036","country":"Spain","contacts":[{"name":"Pablo Iglesias García","role":"CONTACT","phone":"+34 93 227 98 67","email":"piglesia@recerca.clinic.cat"},{"name":"Paula Aguilera Peiro","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Karolinska University Hospital","status":"RECRUITING","city":"Stockholm","state":"Sweden","zip":"141 86","country":"Sweden","contacts":[{"name":"Staffan Wahlin, MD, Associate Professor","role":"CONTACT","phone":"+468585 87984","email":"staffan.wahlin@ki.se"},{"name":"Staffan Wahlin, MD, Associate Professor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Guy's and St Thomas' NHS Foundation Trust","status":"RECRUITING","city":"London","state":"England","zip":"SE1 9RT","country":"United Kingdom","contacts":[{"name":"Neil Songsong","role":"CONTACT","phone":"077 1769 7435","email":"prince.songsong@nhs.net"},{"role":"CONTACT","email":"DermatologyTrials@gstt.nhs.uk"},{"name":"Robert Sarkany","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D046351","term":"Protoporphyria, Erythropoietic"},{"id":"C567464","term":"Protoporphyria, Erythropoietic, X-Linked Dominant"},{"id":"D011164","term":"Porphyrias"}],"ancestors":[{"id":"D017094","term":"Porphyrias, Hepatic"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D012873","term":"Skin Diseases, Genetic"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C550631","term":"(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone"}]}},"hasResults":false}
]}